Daiichi Sankyo Inc Company Profile

✉ Email this page to a colleague

What is the competitive landscape for DAIICHI SANKYO INC, and when can generic versions of DAIICHI SANKYO INC drugs launch?

DAIICHI SANKYO INC has six approved drugs.

There are seventeen US patents protecting DAIICHI SANKYO INC drugs.

There are two hundred and ninety-three patent family members on DAIICHI SANKYO INC drugs in forty-five countries and twenty-three supplementary protection certificates in fifteen countries.

Summary for Daiichi Sankyo Inc

International Patents:	293
US Patents:	17
Tradenames:	6
Ingredients:	6
NDAs:	6

Drugs and US Patents for Daiichi Sankyo Inc

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign up for a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Daiichi Sankyo Inc	EFFIENT	prasugrel hydrochloride	TABLET;ORAL	022307-001	Jul 10, 2009	AB	RX	Yes	No		See Plans and Pricing				See Plans and Pricing
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-001	Aug 2, 2019		RX	Yes	Yes	10,189,833	See Plans and Pricing				See Plans and Pricing
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-001	Aug 2, 2019		RX	Yes	Yes	9,169,250	See Plans and Pricing		Y		See Plans and Pricing
Daiichi Sankyo Inc	MORPHABOND ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	206544-001	Oct 2, 2015		DISCN	Yes	No	7,955,619	See Plans and Pricing	Y			See Plans and Pricing
Daiichi Sankyo Inc	WELCHOL	colesevelam hydrochloride	BAR, CHEWABLE;ORAL	210895-001	Apr 3, 2019		DISCN	Yes	No	7,229,613	See Plans and Pricing				See Plans and Pricing
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-001	Aug 2, 2019		RX	Yes	Yes	9,358,235	See Plans and Pricing				See Plans and Pricing
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-001	Aug 2, 2019		RX	Yes	Yes		See Plans and Pricing				See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Daiichi Sankyo Inc

Subscribe to access the full database, or Sign up for a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Daiichi Sankyo Inc	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	5,580,880	See Plans and Pricing
Daiichi Sankyo Inc	EFFIENT	prasugrel hydrochloride	TABLET;ORAL	022307-001	Jul 10, 2009	6,693,115	See Plans and Pricing
Daiichi Sankyo Inc	WELCHOL	colesevelam hydrochloride	BAR, CHEWABLE;ORAL	210895-001	Apr 3, 2019	7,229,613	See Plans and Pricing
Daiichi Sankyo Inc	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	5,340,821	See Plans and Pricing
Daiichi Sankyo Inc	EFFIENT	prasugrel hydrochloride	TABLET;ORAL	022307-002	Jul 10, 2009	5,288,726*PED	See Plans and Pricing
Daiichi Sankyo Inc	EFFIENT	prasugrel hydrochloride	TABLET;ORAL	022307-001	Jul 10, 2009	5,288,726*PED	See Plans and Pricing
Daiichi Sankyo Inc	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	4,855,290	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for DAIICHI SANKYO INC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Powder for Oral Suspension	1.875 g/Packet and 3.75 g/Packet	➤ Subscribe	2010-04-09
➤ Subscribe	Tablets	15 mg, 30 mg, 60 mg and 100 mg	➤ Subscribe	2019-01-28
➤ Subscribe	Tablets	15 mg, 30 mg and 60 mg	➤ Subscribe	2019-01-28
➤ Subscribe	Tablets	625 mg	➤ Subscribe	2009-07-01
➤ Subscribe	Capsules	30 mg	➤ Subscribe	2009-02-27
➤ Subscribe	Tablets	5 mg and 10 mg	➤ Subscribe	2013-07-10

International Patents for Daiichi Sankyo Inc Drugs

Subscribe to access the full database, or Sign up for a Free Trial
Country	Patent Number	Estimated Expiration
Canada	2451605	See Plans and Pricing
Mexico	336789	See Plans and Pricing
Croatia	P20201383	See Plans and Pricing
Spain	2304437	See Plans and Pricing
Japan	5919253	See Plans and Pricing
South Africa	200906182	See Plans and Pricing
Australia	2008286914	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Daiichi Sankyo Inc Drugs

Subscribe to access the full database, or Sign up for a Free Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0542411	SPC/GB09/032	United Kingdom	See Plans and Pricing	PRODUCT NAME: PRASUGREL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/08/503/001 20090225; UK EU/1/08/503/002 20090225; UK EU/1/08/503/003 20090225; UK EU/1/08/503/004 20090225
1405852	15C0068	France	See Plans and Pricing	PRODUCT NAME: EDOXABAN,UN SEL,SOLVATE OU N-OXYDE DE CELUI-CI,EN PARTICULIER L'EDOXABAN TOSYLATE; REGISTRATION NO/DATE: EU/1/15/993 20150619
2140867	PA2018005,C2140867	Lithuania	See Plans and Pricing	PRODUCT NAME: EDOKSABANAS, JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, ARBA BET KURIO IS JU HIDRATAS, YPAC EDOKSABANO P-TOLUENSULFONATO MONOHIDRATAS; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619
0764174	SPC/GB04/031	United Kingdom	See Plans and Pricing	PRODUCT NAME: COLESEVELAM HYDROCHLORIDE; REGISTERED: UK EU/1/03/268/001-003 20040310
0764174	C300159	Netherlands	See Plans and Pricing	PRODUCT NAME: COLESEVELAM, DESGEWENST IN DE VORM VAN EEN; REGISTRATION NO/DATE: EU/1/03/268/001 20040310
1405852	C01405852/01	Switzerland	See Plans and Pricing	PRODUCT NAME: EDOXABAN; REGISTRATION NO/DATE: SWISSMEDIC 65149 31.03.2015
0542411	C300397	Netherlands	See Plans and Pricing	PRODUCT NAME: PRASUGREL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/08/503/001-014 20090225
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description